Single-minded Shire finally pins down Baxalta with $32B deal

Carly Helfand The new year has its first megadeal agreement, thanks to Shire and Baxalta. On Monday, the two finally announced a $ 32 billion tie-up after a months-long pursuit by ...

Landmark $1.9B-plus deal for Seres includes PhIII support

John Carroll FierceBiotech News

KaloBios files for bankruptcy in the shadow of Shkreli’s arrest

Damian Garde KaloBios was days away from shutting its doors for good when controversial entrepreneur Martin Shkreli swooped in to keep the company afloat last month. Now, with its purported ...

Big Pharma’s steady double-digit price hikes cost Medicare billions

Tracy Staton A new report from the Center for Medicare and Medicaid Services highlights some commonly used meds whose sales growth–and Medicare spending–depends more on ...

Onslaught of new drugs will shake up MS, diabetes, cancer and more

Tracy Staton A bumper crop of FDA approvals in 2015 means an equal number of launches to keep an eye on in 2016. Last year, FiercePharmaMarketing brought you a list of 8 markets to ...

Think different? Pharma turns to tech partnerships for beyond-the-pill moves

Tracy Staton There's not going to be a beyond-the-pill revolution in 2016. Frankly, pharma doesn't yet have the technology to move beyond pushing products to delivering outcomes. ...

VCs: Venture funding grows, with more money for startups

John Carroll That IPO boom was just what the VC doctor ordered. Between high-priced buyout deals and new offerings, the venture funds got the exits they needed to look good to investors ...

The biosimilars are coming. But how long will it be till they can make their mark?

Emily Wasserman Biosimilars have made a splash in Europe, Australia and India, and now they're gaining steam stateside. That's sure to continue, with Citigroup analysts estimating ...

Amgen’s PCSK9 outcomes trial to deliver data sooner than expected

Tracy Staton The wait for outcomes data on Amgen's PCSK9 drug Repatha just got shorter. As CardioBrief reports, top-line results of a study called Fourier will be available in the ...

AstraZeneca shrugs off pharma’s emerging markets slowdown, but Lilly’s suffering

Carly Helfand After Q2's glacial emerging markets growth, industry watchers wondered just how slow pharma could go in developing countries. As it turns out, they found a way to ...

Shire prepared to walk on Baxalta talks if deal doesn’t come soon: WSJ

Carly Helfand Whether it ends in a tie-up or not, Shire's 6-month pursuit of Baxalta is about to come to a close. That's the word from a Wall Street Journal source close to ...

UPDATED: Sanofi’s and Regeneron’s Praluent wins top billing on UnitedHealth Group’s formulary

Eric Palmer Sanofi and Regeneron's Praluent will be UnitedHealth Group's "preferred" drug for treating superhigh LDL cholesterol. The partners said that UnitedHealth ...
© 2018 Global Regulatory Science. All rights reserved. Site Admin · Entries RSS · Comments RSS